Adenosine vs Magnesium Sulphate as Adjuvants in Erector Spinae Plane block for post operative analgesia in patients undergoing Laproscopic Cholecystectomy : A Randomized Clinical Trial - Nil

开始日期2024-12-15

申办/合作机构-

ChiCTR2400092051

/ Suspended早期临床1期IIT

Research on Safety and Efficacy of Adjunctive Intra-arterial adenosine following Successful Endovascular Thrombectomy in Patients with Large Vessel Occlusion Acute Ischemic Stroke

开始日期2024-11-11

申办/合作机构-

NCT06717685

/ Recruiting临床3期IIT

Comparison of Verapamil With Adenosine After Vagal Maneuvers in Patients Presenting With Paroxysmal Supraventricular Tachycardia (pSVT), in a Tertiary Care Hospital of Lahore, Pakistan

Supraventricular tachycardia (SVT) is a term widely used to describe tachycardial dysrhythmias, paroxysmal SVT (PSVT) is a narrow term including only AV nodal re-entrant tachycardia (AVNRT) and atrioventricular re-entrant tachycardia (AVRT), both of which can cause discomfort and, in some cases, life-threatening symptoms.
Usually Carotid sinus massage is done to lower the pulse rate and after the standard time specific verapamil dose is administered. In this study after carotid sinus massage Conventional Valsalva or modified Valsalva maneuver will be randomly applied. In case, the normal sinus rhythm (NSR) is not achieved then verapamil of or adenosine dose will be administered to the patients after after taking the consent.

开始日期2024-10-28

申办/合作机构

Rashid Latif Medical College

[+1]

100 项与腺苷相关的临床结果

登录后查看更多信息

100 项与腺苷相关的转化医学

登录后查看更多信息

100 项与腺苷相关的专利（医药）

登录后查看更多信息

40,340

项与腺苷相关的文献（医药）

2025-12-31·Virulence

Staphylococcus aureus nt5 gene mutation through CRISPR RNA-guided base editing weakens bacterial virulence and immune evasion

Article

作者: Ye, Yang ; Xia, Zijing ; Wang, Haiyi ; Deng, Shi ; He, Fuqiang ; Dai, Ruiwu ; Liang, Shufang ; Liu, Xinpeng ; Tang, Min ; Huang, Lan ; Zhang, Peng

The resistance of commonly used clinical antibiotics, such as daptomycin (DAP), has become increasingly serious in the fight against Staphylococcus aureus (S. aureus) infection. It is essential to explore key pathogenicity-driven genes/proteins in bacterial infection and antibiotics resistance, which contributes to develop novel therapeutic strategies against S. aureus infections. The nt5 gene of S. aureus, encoding 5'-nucleotidase (NT5), is nearly unknown for its function in drug resistance and bacterial infection. Herein, to reveal nt5 gene role in drug resistance and infection ability of S. aureus, we performed nt5^C166T gene mutation using a clustered regulatory interspaced short palindromic repeat ribonucleic acid (RNA)-guided base editing system to investigate the lose-of-function of NT5 protein. Subsequent transcriptome sequencing of the mutant strain revealed that nt5 inactivation caused changes in cell membrane integrity and inhibited nucleotide metabolism, suggesting the nt5 gene may be involved in bacterial drug resistance and virulence. The mutant strain exhibited enhanced tolerance to DAP treatment by attenuating cell membrane potential dissipation and slowing deoxyribonucleic acid release. Moreover, the nt5 mutation alleviated abscess degree of mouse kidneys caused by S. aureus infection byreducing the expression of IL-1β, IL-6, and IL-18. The nt5 mutant strain was easily swallowed by host immune cells, resulting in weak bacterial toxicity of the S. aureus mutant in the bacterial infection process. In summary, nt5 gene mutation confers tolerance to DAP and a lower bacterial capacity to form kidney abscesses through phagocytosis of host immune cells, which indicates the targeted inhibition of NT5 protein would offer a potential new therapeutic strategy against S. aureus infection.

2025-12-01·INFLAMMATION RESEARCH

Comparative analysis of adenosine 1 receptor expression and function in hippocampal and hypothalamic neurons

Article

作者: Wegmann, Lea ; Haas, Helmut L ; Sergeeva, Olga A

Abstract:

Background:

Adenosine, an ATP degradation product, is a sleep pressure factor. The adenosine 1 receptor (A1R) reports sleep need. Histaminergic neurons (HN) of the tuberomamillary nucleus (TMN) fire exclusively during wakefulness and promote arousal. All of them express GABAA receptors and are inhibited by GABA. Does adenosine contribute to their silencing?

Subjects and treatment:

Responses to adenosine were studied in mouse brain slices and primary dissociated cultures. For HN identification single-cell (sc)RT-PCR, reporter protein and pharmacology were used. Hippocampal Dentate Gyrus granular layer cells (DGgc) were studied in parallel.

Methods:

Firing frequency was recorded in patch-clamp configuration or by microelectrode arrays. A1R-expression was studied by scRT-PCR and semiquantitative PCR.

Results:

Most DGgc were inhibited through A1R, detected with scRT-PCR in 7 out of 10 PDZd2-positive DGgc; all HN were A1R negative. One HN out of 25 was inhibited by adenosine. The A1R mRNA level in the hippocampus was 6 times higher than in the caudal (posterior) hypothalamus. Response to adenosine was weaker in hypothalamic compared to hippocampal cultures.

Conclusions:

Most HN are not inhibited by adenosine.

2025-07-01·CELLULAR SIGNALLING

Extracellular ATP and structurally related molecules potentiate adenosine A2a receptor-stimulated cAMP production

Article

作者: Chidiac, Peter ; Wang, Fang I ; Dixon, S Jeffrey

Extracellular ATP has been reported to potentiate signalling by several Class B G protein-coupled receptors (GPCRs). The adenosine A_2a receptor (A_2aR) is a Class A GPCR that regulates many physiological processes, and a potential therapeutic target for many diseases. In vivo, A_2aR is exposed transiently to extracellular ATP within the cellular microenvironment under both physiological and pathological conditions. The modulating effects of extracellular ATP seen with Class B GPCRs have not previously been investigated in other classes of GPCRs. In the present study, we investigated the effects of extracellular ATP on A_2aR signalling. We also studied the actions of similar molecules to explore the structure-activity relationship. Cyclic 3',5'-adenosine monophosphate (cAMP) levels were monitored following agonist-induced receptor activation in cells co-transfected with plasmids encoding A_2aR and a luminescent cAMP biosensor. Extracellular ATP increased the potency of both adenosine and selective A_2aR agonists by approximately an order of magnitude. In the absence of agonist, ATP did not activate A_2aR, arguing against an effect due to ATP metabolism to adenosine. The potentiating effect of ATP was mimicked by other nucleotides and similarly by phosphorylated sugars. Non-phosphorylated sugars produced comparable effects, but higher concentrations were required to do so. This difference in potency implies that the phosphate group is important for modulating A_2aR activity. Here, we present the first evidence that A_2aR can be positively modulated by extracellular ATP, thus the effect of ATP is not limited to Class B GPCRs.

113

项与腺苷相关的新闻（医药）

2025-03-31

·生物探索

Nature Biotechnology | 基因编辑再升级：RNA精准“微调”时代来临！

引言近年来，基因编辑技术如同生物医学领域的一颗璀璨明星，吸引着全球科学家的目光。CRISPR-Cas9等DNA编辑技术的出现，为治疗遗传性疾病带来了前所未有的希望。然而，如同硬币的两面，DNA编辑技术在展现巨大潜力的同时，也面临着一些技术瓶颈，其中最令人担忧的就是“脱靶效应”（off-target editing）。这种效应指的是编辑工具可能会意外地修改基因组中非目标区域的DNA序列，从而引发潜在的副作用。研究人员一直在努力寻找更加精准、安全的基因编辑方法。现在，一个令人振奋的消息传来！3月26日一项发表在《Nature Biotechnology》上的研究“Specific and efficient RNA A-to-I editing through cleavage of an ADAR inhibitor”，为我们带来了全新的解决方案。研究人员不再直接“操刀”DNA，而是将目光投向了它的“信使”——RNA（核糖核酸）。他们开发出了一种名为RNA转换腺嘌呤碱基编辑器（RNA transformer adenosine base editor，RtABE）的创新技术。这项技术能够对RNA上的特定碱基进行精确的修改，就像给RNA进行了一次精密的“微调”，更重要的是，它展现出了惊人的靶向性（specificity），有望彻底告别“脱靶”的困扰，为疾病治疗开辟一条更安全、更高效的道路。告别“脱靶”烦恼：RtABE如何实现RNA的“指哪打哪”？要理解RtABE的独特之处，我们首先需要了解DNA和RNA在细胞中的作用。DNA是细胞的“总司令部”，存储着所有的遗传信息。而RNA则像是“信使”和“执行官”，负责将DNA的指令传递给蛋白质工厂，并直接参与蛋白质的合成。许多疾病的发生，都与RNA分子的异常有关。因此，对异常的RNA进行精准的编辑和修复，同样可以达到治疗疾病的目的。RtABE的核心优势在于其极高的靶向性。为了实现这一点，研究团队巧妙地利用了一类被称为ADAR抑制剂（ADAR inhibitors，ADIs）的分子。ADAR（adenosine deaminase acting on RNA）是一类天然存在的RNA编辑酶，而RtABE的关键组成部分正是ADAR2的脱氨酶结构域（ADAR2 deamination domain，ADAR2DD），它负责将RNA上的腺嘌呤（A）碱基转化为肌苷（I），而肌苷在细胞中会被识别为鸟嘌呤（G）。那么，如何才能让ADAR2DD只在目标RNA位点发挥作用，而不去编辑其他RNA分子呢？这正是RtABE设计的精妙之处。“分子锁”与“精准钥匙”：RtABE特异性编辑背后的设计研究人员将ADI与ADAR2DD巧妙地融合在一起，形成一个“分子复合物”。在没有到达目标RNA序列时，ADI就像一把“分子锁”，紧紧地抑制住ADAR2DD的活性，使其无法进行RNA编辑。只有当RtABE成功结合到预先设定的目标RNA序列后，一个被称为TEV蛋白酶（TEV protease）的“精准钥匙”才会发挥作用。具体来说，研究团队利用了MS2噬菌体衣壳蛋白（MS2 coat protein，MCP）与MS2 RNA发夹结构（MS2 RNA aptamer）的特异性结合，以及BoxB RNA发夹结构（BoxB RNA aptamer）与λ噬菌体N蛋白（λN peptide）的相互作用。他们将MCP融合到ADAR2DD-ADI复合物上，并设计了一段包含MS2和BoxB RNA发夹结构的引导RNA（engineered agRNA，eagRNA）。同时，他们还引入了TEV蛋白酶的N端片段（TEVn）和C端片段（TEVc），其中TEVc与λN肽融合。当eagRNA与目标RNA结合后，MCP-ADAR2DD-ADI复合物会被招募到目标位点。与此同时，游离的TEVn也会扩散到目标位点，并与TEVc结合，形成完整的、具有活性的TEV蛋白酶（TEVp）。TEVp能够特异性地识别并切割ADI，解除ADI对ADAR2DD的抑制。一旦“分子锁”被打开，ADAR2DD就会被激活，开始高效地对目标RNA上的腺嘌呤进行编辑，将其转化为肌苷。这种“先抑制后激活”的策略，就好比一把只有在特定条件下才能解锁的工具，确保了RtABE只在目标RNA位点进行编辑，从而实现了极高的编辑特异性，有效避免了“脱靶”效应的发生。示意图（Credit: Nature Biotechnology）小鼠模型显神威：RtABE成功治疗罕见病带来新希望为了验证RtABE技术的有效性和安全性，研究团队选择了一种名为黏多糖贮积症I型（Hurler syndrome）的罕见遗传病小鼠模型进行实验。这种疾病是由于编码α-L-艾杜糖醛酸酶（α-L-iduronidase，IDUA）的基因发生突变，导致患者体内无法正常分解特定的糖类物质，进而引发一系列严重的健康问题，包括骨骼畸形、智力障碍和器官功能衰竭。研究人员通过腺相关病毒（adeno-associated virus，AAV）将编码RtABE的遗传物质递送到患病小鼠的肝脏细胞中。肝脏是合成和分泌α-L-艾杜糖醛酸酶的主要器官。实验结果令人惊喜！研究发现，经过RtABE治疗后，小鼠肝脏细胞中α-L-艾杜糖醛酸酶的活性得到了显著恢复。这表明RtABE成功地对突变的RNA进行了编辑，产生了功能正常的酶。更重要的是，研究团队对接受RtABE治疗的小鼠的多个组织（包括肝脏、脾脏、肾脏、心脏和大脑）进行了全面的脱靶编辑分析。他们利用高通量测序技术，检测了这些组织中是否存在非目标RNA的编辑事件。结果显示，与传统的RNA编辑方法相比，RtABE的脱靶编辑水平非常低，几乎可以忽略不计。这充分证明了RtABE具有出色的靶向性和安全性，为将其应用于临床治疗罕见病奠定了坚实的基础。此外，研究人员还检测了接受RtABE治疗的小鼠的疾病相关指标。他们发现，经过治疗后，小鼠体内与黏多糖贮积相关的代谢产物水平显著降低，疾病症状得到了明显的改善。这些结果进一步证实了RtABE在治疗黏多糖贮积症I型方面的巨大潜力。多重实验验证：RtABE展现高效性和广谱性除了在黏多糖贮积症I型小鼠模型中的成功应用，研究团队还进行了多项额外的实验，以更全面地评估RtABE技术的性能。他们设计了不同的引导RNA（eagRNA），靶向不同的RNA序列，发现在多种不同的序列背景下（包括UAN、AAN、CAN和GAN等），RtABE都能够高效地进行A-to-I的编辑。这表明RtABE具有广泛的适用性，可以用于编辑各种不同的RNA靶点。为了进一步验证RtABE的特异性，研究人员还进行了敲低实验（knockdown experiment）。他们利用小干扰RNA（small interfering RNA，siRNA）敲低了目标RNA的表达，结果发现RtABE的编辑活性也随之显著降低。这表明RtABE的编辑是高度依赖于目标RNA的存在的，进一步证实了其靶向性。研究人员还通过蛋白质印迹法（Western blot）分析了在目标转录本被敲低时A3DADI的切割情况，结果与RT-qPCR数据一致，进一步支持了RtABE的作用机制。此外，研究团队还对RtABE的组成部分进行了优化，例如对ADAR2DD进行了突变改造（E488Q），以进一步提高其编辑效率和特异性。他们还探索了不同的递送方式，例如利用腺相关病毒（AAV）进行体内递送，为未来的临床应用提供了更多的选择。这些多方面的实验结果充分证明，RtABE是一种高效、特异性强、且具有广谱性的RNA编辑工具，在基础研究和疾病治疗领域都具有巨大的潜力。RNA编辑潜力无限：未来医学领域的新星冉冉升起DNA编辑技术无疑是基因治疗领域的重要里程碑，但RNA编辑作为一种新兴的技术，也展现出了独特的优势和广阔的应用前景。与DNA编辑相比，RNA编辑具有以下几个显著的特点：更高的安全性：RNA的半衰期较短，编辑效果通常是暂时的，不会对基因组造成永久性的改变，从而降低了潜在的长期副作用风险。这对于一些只需要短期治疗的疾病来说，具有明显的优势。更强的可调控性：RNA的表达水平和修饰状态可以受到多种细胞信号和环境因素的调控，这为疾病治疗提供了更加灵活的策略。例如，我们可以根据疾病的进展情况，动态地调整RNA编辑的效率。更广泛的应用范围：除了遗传性疾病，RNA编辑在感染性疾病、神经退行性疾病、癌症等多个领域都展现出了巨大的潜力。例如，通过编辑病毒的RNA，可以抑制病毒的复制；通过编辑肿瘤细胞的RNA，可以抑制肿瘤的生长和转移；通过编辑神经细胞的RNA，可以延缓神经退行性疾病的进展。RtABE技术的出现，正是RNA编辑领域的一项重大突破。它解决了RNA编辑长期以来面临的关键挑战——特异性问题，使得RNA编辑技术在疾病治疗方面迈出了坚实的一步。许多研究人员认为，随着技术的不断成熟和完善，RNA编辑有望成为继DNA编辑之后，基因治疗领域的又一个“风口”，为人类健康带来更多的福音。精准医疗新篇章：RtABE引领基因治疗迈向更安全高效的未来总而言之，这项名为RtABE的RNA编辑新技术，通过巧妙地融合ADAR抑制剂和TEV蛋白酶系统，实现了对RNA的精准编辑，有效克服了传统基因编辑技术可能存在的“脱靶”难题。在黏多糖贮积症I型小鼠模型中取得的成功，充分证明了RtABE在治疗遗传性疾病方面的巨大潜力。这项研究的突破性进展，不仅为治疗罕见病带来了新的希望，也为RNA编辑技术在更广泛的疾病领域应用奠定了坚实的基础。我们有理由相信，随着未来研究的不断深入和技术的持续发展，RNA编辑技术将在精准医疗时代发挥越来越重要的作用，为人类的健康福祉贡献力量。让我们共同期待这项令人兴奋的技术能够早日走向临床，造福更多的患者！参考文献Li G, Chen G, Yuan GH, Wei J, Ni Q, Wu J, Yang B, Yang L, Chen J. Specific and efficient RNA A-to-I editing through cleavage of an ADAR inhibitor. Nat Biotechnol. 2025 Mar 26. doi: 10.1038/s41587-025-02591-2. Epub ahead of print. PMID: 40140558.责编|探索君排版|探索君转载请注明来源于【生物探索】声明：本文仅用于分享，不代表平台立场，如涉及版权等问题，请尽快联系我们，我们第一时间更正，谢谢！End往期精选围观Science | 你每天吃的食用油，可能正在悄悄喂养癌细胞热文Nature Methods | 癌症治疗大翻盘：长读长测序揭开73%漏诊的致命靶点热文Nature | 颠覆百年认知！肝脏"纤维化元凶"竟是代谢再生总指挥热文Science | 心脏发育暗藏的"生物光缆"如何颠覆医学认知？热文Nature | 线粒体的"能量之门"被破解：研究人员首次看清代谢引擎的分子开关

基因疗法核酸药物

2025-03-30

·学术经纬

《自然》子刊：精准、广谱的RNA碱基编辑器，可实现高效基因编辑

▎药明康德内容团队编辑（来源：上海科技大学）新兴的RNA编辑技术为纠正致病基因突变提供了新方法和新策略。与DNA编辑不同，RNA编辑只会瞬时改变由DNA转录产生的RNA转录本，避免了DNA编辑脱靶所带来的长期安全性风险。目前已报道有两种腺苷脱氨酶ADAR（adenosine deaminase acting on RNA）依赖的靶向RNA腺苷至肌苷（A-to-I）的编辑系统，但分别有高脱靶、编辑范围和编辑效率受限的问题。近日，上海科技大学生命科学与技术学院陈佳团队和复旦大学杨力团队合作在《自然-生物技术》（Nature Biotechnology）在线发表了题为“Specific and efficient RNA A-to-I editing through cleavage of an ADAR inhibitor ”的研究论文，报道了一种高效、精准且具有广泛编辑范围的RNA变形式腺苷碱基编辑系统RtABE（RNA transformer Adenosine Base Editor）。本研究对ADAR2脱氨结构域（ADAR2DD）具有潜在抑制作用的蛋白结构域进行了筛选，发现某些胞苷脱氨酶家族APOBEC的脱氧胞苷脱氨酶抑制结构域（deoxycytidine deaminase inhibitor，dCDI）也可以作为ADAR抑制剂（ADAR inhibitor，ADI）。在RtABE系统中，将来源于人APOBEC3蛋白的ADI（A3DADI）和ADAR2DD融合表达从而抑制其脱氨活性。在脱靶位点，由于A3DADI和ADAR2DD的融合连接，ADAR2DD蛋白保持无活性状态；而在靶向位点处，通过工程化改造的导向RNA（engineered ADAR guide RNA，eagRNA），招募分裂的TEV蛋白酶和ADAR2DD-A3DADI的融合蛋白，切除A3DADI结构域，将ADAR2DD蛋白由抑制状态转化为激活状态，完成靶向编辑。▲图1：RtABE工作机制示意图（图片来源：原始论文[1]）为了进一步提高RtABE的精准性，本研究利用蛋白质工程引入了ADAR2DD（K475Q+E488Q）和ADAR2DD（K475I+S486A）两种突变体，得到了RtABE_V1和RtABE_V2系统。RtABE在全转录组范围内实现了脱靶效应的显著降低，同时保持了在靶向位点处的高编辑效率。相对于使用工程化RNA招募内源ADAR的RNA编辑器，RtABE系统实现了在更大的编辑范围内的高效编辑（例如，UAN，AAN，CAN和GAN）。将RtABE包装到单一的腺相关病毒（AAV）后递送至Hurler综合征（粘多糖病I型）模型小鼠中，结果显示RtABE系统在Hurler综合征模型小鼠体内实现了长期、高效和精准的RNA A-to-I碱基编辑，同时并未在RtABE处理过的小鼠的肝脏中检测到显著性的脱靶编辑。因此，RtABE是一种精准、高效的RNA碱基编辑系统，且具有广泛的编辑范围。▲图2：RNA编辑系统RtABE_V2和MCP-ADAR2DD的功效比较（图片来源：原始论文[1]）基于联合研究团队在疾病模型小鼠中的研究结果，RtABE为遗传性疾病以及其他人类严重疾病的潜在临床治疗应用提供了新希望。上海科技大学生命科学与技术学院基因编辑中心陈佳教授及复旦大学生物医学研究院杨力研究员为该论文的共同通讯作者。上海科技大学陈佳课题组博士研究生李光业、陈果，中国科学院上海营养与健康研究所博士研究生袁国华，复旦大学附属儿科医院实验师韦佳为该论文共同第一作者。上海科技大学为论文的第一完成单位。原始论文：[1] Li, G., Chen, G., Yuan, GH. et al. Specific and efficient RNA A-to-I editing through cleavage of an ADAR inhibitor. Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02591-2免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。更多推荐点个“在看”再走吧~

基因疗法核酸药物

2025-03-28

·BioSpace

Milestone Stock Crashes After Surprise Tachycardia Drug Rejection

iStock, Tymofii Riabets Milestone Pharmaceuticals hit another bump in the road in its quest to get Cardamyst approved for paroxysmal supraventricular tachycardia when the FDA issued a Complete Response Letter on Friday. Milestone Pharmaceuticals revealed on Friday that the FDA has rejected its cardiovascular drug Cardamyst, sending the company’s shares down by more than 60%. The complete response letter, which focused on two key chemistry, manufacturing and controls (CMC) issues, is the latest knock in the Montreal and Charlotte, N.C.–based company’s quest to get Cardamyst approved for paroxysmal supraventricular tachycardia (PSVT), a type of abnormal heart rhythm affecting around 2 million people in the U.S. In December 2023, the FDA hit Milestone with a Refusal to File letter for the nasal spray, saying the company’s application was not sufficient to warrant a full review. Milestone refiled its application in March 2024 with additional information, including restructured data sets that captured the timing of reported adverse events. The FDA accepted the application in May of that year. The rejection may have come as a surprise to Milestone, which had been actively preparing for the drug’s launch. In an interview earlier this week, CEO Joe Oliveto told BioSpace the company was “transitioning to a commercial organization” and had already hired the sales management team for Cardamyst’s rollout but was waiting for formal approval before issuing offers to sales representatives. In its CRL, the FDA requested that Milestone submit additional information on nitrosamine impurities based on a new draft guidance issued after the new drug application was submitted and complete an inspection at the facility that performs release testing for Cardamyst. The facility had changed ownership during the review process, according to Milestone. There is high unmet need for patients with PSVT, which is characterized by episodes of rapid heart rate often exceeding 150 to 200 beats per minute. The condition instills a lot of fear in patients because “you don’t know when [events are] going to come and how bad it’s going to be and how long it’s going to last,” Oliveto said. Cardamyst offers patients “a little bit of peace of mind.” A novel calcium channel blocker, Cardamyst is formulated to deliver IV-like potency in the convenience of a nasal spray, Oliveto explained, so patients can manage PSVT events wherever they occur without needing to go to the hospital. PSVT is somewhat of an orphan indication, as “there’s no one else working in the space,” Oliveto said. There have been advances in an ablation procedure where doctors use small radio waves to destroy a small amount of heart tissue that might trigger PSVT, he noted. However, Cardamyst would be the first new drug for the condition since adenosine , an intravenous drug used in emergency rooms, was approved by the FDA in 1989. In its NDA submission, Milestone touted a “comprehensive data package” from the pivotal Phase III RAPID trial that suggested the drug was “twice as effective and three times as fast as placebo” in normalizing heart rhythm. Cardamyst is also in Phase II development for another cardiovascular disease, atrial fibrillation. In this indication, “there are interventions in development, but they’re really more for anticoagulants,” Oliveto said. There are “none to actually treat the episode in the moment like [Cardamyst] will be.” Responding to the rejection, Oliveto said in a statement: “We are deeply disappointed by the CRL but remain committed to the potential of Cardamyst as a novel treatment option that can help patients with PSVT.” The company intends to request a Type A meeting with the FDA to discuss the issues raised in the CRL, he added.

临床3期上市批准临床2期临床结果AHA会议

100 项与腺苷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00045	腺苷	C01EB10	DB00640

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心脏病	日本	Daiichi Sankyo Co., Ltd.	2005-04-11
心动过速	中国	Sanofi Winthrop	2000-02-19
室上性心动过速	美国	Astellas Pharma US, Inc.	1989-10-30

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
冠心病	临床3期	美国	Astellas Pharma US, Inc.	2010-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESC2024	N/A	心肌桥	-	Adenosine infusion	憲艱餘鬱廠艱艱膚齋衊(鑰餘鏇鏇遞積簾膚壓醖) = 憲餘廠餘獵艱齋顧膚積選襯簾顧餘鹹憲獵顧廠 (淵膚餘餘淵夢壓廠製範, 12) 更多	-	2024-08-31
				Dobutamine infusion	憲艱餘鬱廠艱艱膚齋衊(鑰餘鏇鏇遞積簾膚壓醖) = 築範衊廠簾觸夢衊網願選襯簾顧餘鹹憲獵顧廠 (淵膚餘餘淵夢壓廠製範, 13) 更多
NCT04392362 (AHAvsSIM, CTgov)	临床3期	室上性心动过速	30	Adenosine (Intervention Group)	觸鬱鹹淵艱夢簾餘鬱繭 = 獵膚積艱網繭積膚醖觸憲廠淵簾顧齋蓋觸廠糧 (網窪顧鑰窪觸獵構積蓋, 蓋壓齋壓艱觸壓醖齋窪 ~ 願鹹齋憲鬱鹹鑰鑰壓積) 更多	-	2021-06-25
				Adenosine (Control Group)	觸鬱鹹淵艱夢簾餘鬱繭 = 窪衊遞齋構鬱餘製夢鹽憲廠淵簾顧齋蓋觸廠糧 (網窪顧鑰窪觸獵構積蓋, 願鹽齋製範製壓糧網選 ~ 艱鹽鹹繭餘膚衊簾窪築) 更多
AAI2021	N/A	-	-	Adenosine Deaminase 1 (ADA-1) (SARS-CoV-2 spike plasmid alone)	廠鬱廠齋鹹鏇網齋觸製(範壓醖選淵鏇鏇鏇構簾) = increased 齋顧鬱窪鹹鑰網繭壓齋 (構簾襯襯鏇糧憲選範鏇 ) 更多	-	2021-05-01
				Adenosine Deaminase 1 (ADA-1) (SARS-CoV-2 spike plasmid + ADA plasmid)
EANM2020	N/A	-	150	adenosine (Reversible perfusion defects)	網蓋構餘齋糧膚鑰襯餘(餘製範餘願鬱構獵衊觸) = 構範選糧憲選憲餘觸齋願積鹹膚網膚構觸鹹膚 (鑰夢廠願夢觸繭鑰蓋淵 )	-	2020-09-18
ESC2020	N/A	慢性阻塞性肺疾病 \| 哮喘	780	Regadenoson	網衊餘淵範構艱窪糧鹽(觸鹽夢範淵鏇糧廠膚觸) = 73% 餘鬱艱夢糧鏇鹹簾膚壓 (願製餘鹽願網範網廠襯 ) 更多	-	2020-08-28
Extreme trial (ESC2019)	N/A	ST段抬高心肌梗死	61	adenosine	積衊齋積選觸獵膚簾鬱(壓網鹹鑰夢醖廠憲鹹願) = 齋餘製築蓋蓋齋齋願鬱簾範衊蓋觸鏇觸艱顧顧 (衊壓構鑰艱蓋製壓觸廠 ) 更多	-	2019-12-06
				adenosine	積衊齋積選觸獵膚簾鬱(壓網鹹鑰夢醖廠憲鹹願) = 糧簾齋鹹窪齋艱製憲鏇簾範衊蓋觸鏇觸艱顧顧 (衊壓構鑰艱蓋製壓觸廠 ) 更多
ACR2019	N/A	风湿性多肌痛 IL-6 \| adenosine \| equilibrative nucleoside transporter 1 (ENT1)	-	Adenosine (Old Tenocytes)	獵廠構網淵廠夢構構衊(膚膚構夢鹹鑰製糧網構) = 網夢觸醖積壓積窪願窪醖糧繭構築願鏇襯繭衊 (艱範蓋鑰鑰築鹹壓齋鹹, 194.3)	-	2019-11-12
				Adenosine (Young Tenocytes)	獵廠構網淵廠夢構構衊(膚膚構夢鹹鑰製糧網構) = 壓繭齋襯築齋獵糧蓋鬱醖糧繭構築願鏇襯繭衊 (艱範蓋鑰鑰築鹹壓齋鹹 )
EANM2019	N/A	-	16	adenosine (Patients with normal myocardial perfusion imaging)	網窪艱鏇齋淵鬱願製襯(築窪壓範簾齋壓艱廠齋) = 鬱鏇膚構鬱襯鹽簾衊簾鬱獵襯製製淵鑰選襯簾 (鬱鬱鏇憲網齋鏇憲積艱, 0.39) 更多	-	2019-09-18
				adenosine (Patients with stress ischemia and reduced flow reserve)	網窪艱鏇齋淵鬱願製襯(築窪壓範簾齋壓艱廠齋) = 鑰構範壓夢積獵製廠醖鬱獵襯製製淵鑰選襯簾 (鬱鬱鏇憲網齋鏇憲積艱, 0.3) 更多
EANM2018	N/A	冠心病	-	Adenosine	構窪觸網鹽憲醖築顧壓(願憲憲鏇糧夢選窪願網) = 醖襯艱夢膚齋範範獵襯積範醖觸積築艱製蓋網 (鬱廠膚糧齋簾遞艱糧鑰, 0.27)	-	2018-09-18
				Regadenoson	構窪觸網鹽憲醖築顧壓(願憲憲鏇糧夢選窪願網) = 鹽窪製積網構範網窪糧積範醖觸積築艱製蓋網 (鬱廠膚糧齋簾遞艱糧鑰, 0.23)
EANM2018	N/A	-	475	Adenosine	衊製網襯壓築繭鏇繭範(願構壓製夢蓋顧壓製製) = 衊簾顧網鑰廠餘鑰顧觸襯鬱蓋蓋襯鏇鹹淵鏇蓋 (襯憲簾觸構窪餘蓋鑰壓 ) 更多	-	2018-09-18
				Regadenoson	衊製網襯壓築繭鏇繭範(願構壓製夢蓋顧壓製製) = 鹹餘築艱顧鏇餘遞糧積襯鬱蓋蓋襯鏇鹹淵鏇蓋 (襯憲簾觸構窪餘蓋鑰壓 ) 更多